



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/802,094	03/08/2001	Paul Calabresi	21486-038	4935

30623 7590 10/06/2004

MINTZ, LEVIN, COHN, FERRIS, GLOVSKY  
AND POPEO, P.C.  
ONE FINANCIAL CENTER  
BOSTON, MA 02111

EXAMINER

YAEN, CHRISTOPHER H

ART UNIT PAPER NUMBER

1642

DATE MAILED: 10/06/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

### **SUPPLEMENTAL EXAMINER'S AMENDMENT**

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Ingrid Beattie on 9/1/2004.

*This Supplemental Examiner's Amendment is to replace the Examiner's Amendment mailed 9/10/2004. Applicant's representative called to indicate that there were minor spelling errors in the claim. In particular, the term "ironotecan" was misspelled and will be replaced with "irinotecan".*

The application has been amended as follows:

**1. - 8. (Cancelled)**

**9. (Currently Amended)** A method of inhibiting tumor cell growth in a mammal, comprising administering to said mammal a composition comprising a thrombospondin polypeptide and an inhibitor of DNA topoisomerase I enzyme activity, wherein said tumor cell is a colon tumor cell, wherein said thrombospondin polypeptide is thrombospondin-1 (TSP-1) or thrombospondin-2 (TSP-2) and said inhibitor of DNA topoisomerase I enzyme activity is irinotecan (CPT-11) ~~a water-soluble camptothecin compound~~, and wherein administering the composition produces a synergistic

Art Unit: 1642

antineoplastic effect in said mammal such that tumor growth is inhibited in the presence of said thrombospondin polypeptide and said irinotecan (CPT-11) ~~water-soluble camptothecin compound~~ compared to in the absence of said thrombospondin polypeptide and said irinotecan (CPT-11) ~~water-soluble camptothecin compound~~.

10. - 11. **(Cancelled)**

12. **(Previously Presented)** The method of claim 9, wherein said thrombospondin polypeptide is thrombospondin-1.

13. **(Previously Presented)** The method of claim 9, wherein said thrombospondin polypeptide is thrombospondin-2.

14. -16. **(Cancelled)**

17. **(Original)** The method of claim 9, wherein said mammal is a human.

18. **(Previously Presented)** The method of claim 9, wherein said thrombospondin polypeptide is administered prior to said inhibitor of DNA topoisomerase I enzyme activity.

19. **(Previously Presented)** The method of claim 9, wherein said inhibitor of DNA topoisomerase I enzyme activity is administered prior to said thrombospondin polypeptide.

20. **(Previously Presented)** The method of claim 9, wherein said thrombospondin polypeptide and said inhibitor of DNA topoisomerase I enzyme activity are administered simultaneously.


**All rejections and or objections are withdrawn in view of the applicant's amendments and arguments thereto as set forth in a paper filed 7/6/2004.**

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher H Yaen whose telephone number is 571-272-0838. The examiner can normally be reached on Monday-Friday 9-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeffrey Siew can be reached on 571-272-0787. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Christopher Yaen  
Art Unit 1642

  
**GARY NICKOL**  
**PRIMARY EXAMINER**